Opinion

Video

The Goals of AML Maintenance Therapy

Catherine E. Lai, MD, MPH, discusses the goals of maintenance therapy, how to manage treatment-related adverse events, and the impact of treatment on patient’s quality of life.

Transcript:

For patients who aren’t able to go to transplant, the goal of therapy is to continue maintenance if that is an option for them to prevent leukemia relapse. We try to keep patients on therapy for as long as they can tolerate it with regard to adverse effects, particularly in terms of quality of life and cytopenias. That is the main concern for patients. There are some GI adverse effects as well. These are all typically manageable and can be alleviated by either dose interruptions or dose holds or decreasing the duration. But it’s important to try to continue the maintenance and just modify your maintenance treatment accordingly so that patients can continue on therapy.

Transcript edited for clarity.

Related Videos
Floortje J. Backes, MD, discusses ongoing research to watch in ovarian cancer.
Floortje J. Backes, MD, discusses other potential roles for mirvatuximab soravtansine and other antibody-drug conjugates in ovarian cancer.
Floortje J. Backes, MD, discusses data for mirvatuximab soravtansine in FRα-positive, platinum-sensitive ovarian cancer
Floortje J. Backes, MD, discusses how to approach FRα testing in ovarian cancer.
Floortje J Backes, MD, discusses how mirvatuximab soravtansine has affected the management of platinum-resistant ovarian cancer.
Floortje J Backes, MD, discusses current treatment considerations for platinum-resistant ovarian cancer.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024..
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for mosunetuzumab in newly diagnosed follicular lymphoma.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss 2-year follow-up data for liso-cel in relapsed/refractory follicular lymphoma.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss CD19 expression and the use of tafasitamab in relapsed/refractory DLBCL.